{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T20:44:41Z","timestamp":1768250681611,"version":"3.49.0"},"reference-count":32,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T00:00:00Z","timestamp":1468454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Respirology"],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background and objective<\/jats:title><jats:p>We aimed to assess the clinical features, aetiology and outcomes of bacteraemic pneumonia in neutropenic cancer patients (<jats:styled-content style=\"fixed-case\">NCP<\/jats:styled-content>) in the current era of increasing antimicrobial resistance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All episodes of bacteraemia occurring in hospitalized patients with cancer, including haematopoietic stem cell transplant recipients, from January 2006 to April 2015 were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 1723 episodes of bacteraemia, of which 795 occurred in neutropenic patients with cancer, and among them, 55 episodes were identified as bacteraemic pneumonia. The most frequent causative agents were <jats:italic>Pseudomonas aeruginosa<\/jats:italic> (39.6%), <jats:italic>Streptococcus pneumoniae<\/jats:italic> (20.6%) and <jats:italic>Escherichia coli<\/jats:italic> (8.6%). Among the Gram\u2010negative organisms, 12.8% were multidrug resistant (<jats:styled-content style=\"fixed-case\">MDR<\/jats:styled-content>). Eleven patients (20%) required admission to intensive care, and eight (14.8%) underwent invasive mechanical ventilation. Nine patients (16.3%) received inadequate empirical antibiotic therapy, of whom six (66.6%) died; eight of these nine patients had pneumonia caused by resistant microorganisms. The early (48\u2009h) case\u2010fatality rate was 24% and the overall (30\u2009day) case\u2010fatality rate was 46.2%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Bacteraemic pneumonia is a frequent complication among <jats:styled-content style=\"fixed-case\">NCP<\/jats:styled-content> and is mainly caused by <jats:italic>P. aeruginosa<\/jats:italic> and <jats:italic>S. pneumoniae<\/jats:italic>. The emergence of <jats:styled-content style=\"fixed-case\">MDR<\/jats:styled-content> organisms is of special concern. Despite the improvement in the management of cancer patients, case\u2010fatality rates of <jats:styled-content style=\"fixed-case\">NCP<\/jats:styled-content> with bacteraemic pneumonia remain high. Urgent assessment is needed to identify a better approach for the management and support of these patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/resp.12848","type":"journal-article","created":{"date-parts":[[2016,7,15]],"date-time":"2016-07-15T01:05:44Z","timestamp":1468544744000},"page":"1411-1418","source":"Crossref","is-referenced-by-count":31,"title":["Clinical features, aetiology and outcome of bacteraemic pneumonia in neutropenic cancer patients"],"prefix":"10.1111","volume":"21","author":[{"given":"Carlota","family":"Gudiol","sequence":"first","affiliation":[{"name":"Departments of Infectious Diseases University of Barcelona, L'Hospitalet de Llobregat  Barcelona Spain"},{"name":"Catalan Institute of Oncology University of Barcelona, L'Hospitalet de Llobregat  Barcelona Spain"},{"name":"Bellvitge Biomedical Research Institute (IDIBELL) University of Barcelona, L'Hospitalet de Llobregat  Barcelona Spain"},{"name":"REIPI (Spanish Network for Research in Infectious Diesaes) ISCIII (Carlos III Health Institute)  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Royo\u2010Cebrecos","sequence":"additional","affiliation":[{"name":"Departments of Infectious Diseases University of Barcelona, L'Hospitalet de Llobregat  Barcelona Spain"},{"name":"Bellvitge Biomedical Research Institute (IDIBELL) University of Barcelona, L'Hospitalet de Llobregat  Barcelona Spain"},{"name":"REIPI (Spanish Network for Research in Infectious Diesaes) ISCIII (Carlos III Health Institute)  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00falia","family":"Laporte","sequence":"additional","affiliation":[{"name":"Departments of Infectious Diseases University of Barcelona, L'Hospitalet de Llobregat  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Ardanuy","sequence":"additional","affiliation":[{"name":"Departments of Microbiology of Bellvitge Univesity Hospital University of Barcelona, L'Hospitalet de Llobregat  Barcelona Spain"},{"name":"CIBERes (CIBEr Respiratory Diseases) ISCIII  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Garcia\u2010Vidal","sequence":"additional","affiliation":[{"name":"Departments of Infectious Diseases University of Barcelona, L'Hospitalet de Llobregat  Barcelona Spain"},{"name":"Bellvitge Biomedical Research Institute (IDIBELL) University of Barcelona, L'Hospitalet de Llobregat  Barcelona Spain"},{"name":"REIPI (Spanish Network for Research in Infectious Diesaes) ISCIII (Carlos III Health Institute)  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maite","family":"Antonio","sequence":"additional","affiliation":[{"name":"Departments of Oncology University of Barcelona, L'Hospitalet de Llobregat  Barcelona Spain"},{"name":"Catalan Institute of Oncology University of Barcelona, L'Hospitalet de Llobregat  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Arnan","sequence":"additional","affiliation":[{"name":"Departments of Haematology Duran i Reynals Hospital University of Barcelona, L'Hospitalet de Llobregat  Barcelona Spain"},{"name":"Catalan Institute of Oncology University of Barcelona, L'Hospitalet de Llobregat  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Carratal\u00e0","sequence":"additional","affiliation":[{"name":"Departments of Infectious Diseases University of Barcelona, L'Hospitalet de Llobregat  Barcelona Spain"},{"name":"Bellvitge Biomedical Research Institute (IDIBELL) University of Barcelona, L'Hospitalet de Llobregat  Barcelona Spain"},{"name":"REIPI (Spanish Network for Research in Infectious Diesaes) ISCIII (Carlos III Health Institute)  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,7,14]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11199-8"},{"key":"e_1_2_6_3_1","first-page":"1255","article-title":"Incidence and outcome of pneumonia in patients with acute leukemia receiving first induction therapy with anthracycline containing regimens","volume":"85","author":"Rossini F","year":"2000","journal-title":"Haematologica"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705561"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-010-0746-y"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000156"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0b013e328351f8e8"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1086\/428046"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704162"},{"key":"e_1_2_6_10_1","doi-asserted-by":"crossref","unstructured":"Aguilar\u2010GuisadoM Jim\u00e9nez\u2010JambrinaM EspigadoI RoviraM MartinoR OriolA BorrellN RuizI Mart\u00edn\u2010D\u00e1vilaP de laC\u00e1maraRet al.Spanish Network for Research in Infectious Diseases. Pneumonia in allogeneic stem cell transplantation recipients: a multicenter prospective study.Clin. Transplant.2011;25:E629\u201338.","DOI":"10.1111\/j.1399-0012.2011.01495.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2012.03879.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2013.12.006"},{"key":"e_1_2_6_13_1","first-page":"CD003344","article-title":"Beta\u2010lactam antibiotic monotherapy versus beta\u2010lactam\u2010aminoglycoside antibiotic combination therapy for sepsis","volume":"1","author":"Paul M","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.16.3038"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"e_1_2_6_16_1","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoints tables for interpretation of MICs and zone diameters. Version 5.0 2015. Available from URL:http:\/\/www.eucast.org."},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.12.700"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.8.868"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-004-1180-y"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/2110-5820-1-5"},{"key":"e_1_2_6_21_1","unstructured":"SoaresM CarusoP SilvaE TelesJM LoboSM FriedmanG Dal PizzolF MelloPV BozzaFA SilvaUVet al.Brazilian Research in Intensive Care Network (BRICNet). Characteristics and outcomes of patients with cancer requiring admission to intensive care units: a prospective multicenter study.Crit. Care Med.2010;38:9\u201315."},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-004-0667-5"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120544"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/SHK.0b013e3182866d32"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-012-2594-0"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000145370.63676.fb"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3182227a27"},{"key":"e_1_2_6_28_1","unstructured":"LemialeV MokartD Resche\u2010RigonM P\u00e8neF MayauxJ FaucherE NyungaM GiraultC PerezP GuittonCet al.Groupe de Recherche en R\u00e9animation Respiratoire du patient d'Onco\u2010H\u00e9matologie (GRRR\u2010OH). Effect of noninvasive ventilation vs oxygen therapy on mortality among immunocompromised patients with acute respiratory failure: a randomized clinical trial.JAMA.2015;314:1711\u20139."},{"key":"e_1_2_6_29_1","doi-asserted-by":"crossref","first-page":"597","DOI":"10.4187\/respcare.01887","article-title":"High\u2010flow nasal cannula therapy in do\u2010not intubate patients with hypoxemic respiratory distress","volume":"58","author":"Peters SG","year":"2013","journal-title":"Respir. Care"},{"key":"e_1_2_6_30_1","first-page":"CD010381","article-title":"Extracorporeal membrane oxygenation for critically ill adults","volume":"1","author":"Tramm R","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_2_6_31_1","unstructured":"FreifeldAG BowEJ SepkowitzKA BoeckhMJ ItoJI MullenCA RaadII RolstonKV YoungJA WingardJR;Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America.Clin. Infect. Dis.2011;52:427\u201331."},{"key":"e_1_2_6_32_1","doi-asserted-by":"crossref","unstructured":"AverbuchD OraschC CordonnierC LivermoreDM MikulskaM ViscoliC GyssensIC KernWV KlyasovaG MarchettiOet al.ECIL4 a joint venture of EBMT EORTC ICHS ESGICH\/ESCMID and ELN. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4thEuropean Conference on Infections in Leukemia.Haematologica2013;98:1826\u201335.","DOI":"10.3324\/haematol.2013.091025"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu192"}],"container-title":["Respirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fresp.12848","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/resp.12848","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:45:39Z","timestamp":1696207539000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/resp.12848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,14]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1111\/resp.12848"],"URL":"https:\/\/doi.org\/10.1111\/resp.12848","archive":["Portico"],"relation":{},"ISSN":["1323-7799","1440-1843"],"issn-type":[{"value":"1323-7799","type":"print"},{"value":"1440-1843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,14]]}}}